Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: Hum Immunol. 2007 Mar 12;68(5):309–323. doi: 10.1016/j.humimm.2007.01.019

Figure 5.

Figure 5

Influence of HLA-C and HLA-B genotype on acute GVHD grade II-IV in all patients with different donor/recipient KIR genotype combinations. A. Kaplan-Meier analysis of grade II-IV acute GVHD in patients who have been grouped according to donor-recipient KIR and recipient HLA-C genotype combination. The equality of all 8 curves was tested (d.f.=7, p=0.005). B. Pairwise comparisons of the curves was then performed by Cox proportional hazard modeling, where the overall type I error rate was controlled by the initial test. Comparison of the probability of aGVHD between donor-Bx/recipient-AA/recipientC2Cx and all other KIR/HLA genotype combinations are shown. C. Kaplan-Meier analysis of aGVHD grade II-IV in patients who are (i) Bw4− (Bw6/Bw6 homozygous) (n=12/81) compared to (ii) patients who have at least one Bw4 allele (Bw4/Bw4 homozygotes or Bw4/Bw6 heterozygotes) (n=34/120, p=0.04; hazard ratio=2.0, 95% CI=1.04-3.9). D. Kaplan-Meier analysis of aGVHD in patients who have been grouped according to donor-recipient KIR and recipient HLA-B genotype combination. The equality of all 8 curves was tested (d.f=7, p=0.1). E. Pairwise comparisons of the curves was then determined by Cox proportional hazard modeling, where the overall type I error rate was controlled by the initial test. Comparison of the probability of aGVHD between donor-Bx/recipient-Bx/recipient-Bw4− and all other KIR/HLA genotype combinations are shown. ‘Bx’ is as defined in Figure 2, ‘C2Cx’ indicates that the individual has at least one C2 haplotype. The second haplotype can either be C1 or C2. Ratios were considered significant when p ≤ 0.05 (bold). In panels B and E, the patient group differing only by HLA type from the group showing the greatest effect was chosen as the reference group to which all other groups were compared.